Concepedia

Psychosis in a 12-Year-Old HIV-Positive Girl with an Increased Serum Concentration of Efavirenz

Elizabeth Lowenhaupt, Kelly L. Matson, Bushra Qureishi, Akihiko Saitoh, David Pugatch

Clinical Infectious Diseases · 2007 · 41 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Clearance and adverse effects of efavirenz are associated with CYP2B6-G516T polymorphism. Little is known about the prevalence of genotypes and implications for screening in children. We report (to our knowledge, for the first time in a child) the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T.

References

10

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

David W. Haas, Heather J. Ribaudo, Richard B. Kim et al. · PubMed · 2004 · 628 citations

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 591 citations

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

Thomas Lang, Kathrin Klein, Joachim E. Fischer et al. · Pharmacogenetics · 2001 · 569 citations

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

Margalida Rotger, Sara Colombo, Hansjakob Furrer et al. · Pharmacogenetics and Genomics · 2005 · 409 citations

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens

K. Tsuchiya, Hiroyuki Gatanaga, Natsuo Tachikawa et al. · Biochemical and Biophysical Research Communications · 2004 · 272 citations

, , +8